GLP-1 Agonist · Metabolic & Diabetes Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
GLP1 is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist, representing the current standard for single-mechanism metabolic peptide research. It mimics endogenous GLP-1 with 94% homology but with extended half-life (~165 hours) due to albumin binding via a C-18 fatty di-acid side chain. With extensive Phase 3 data across diabetes and obesity research, GLP1 serves as a benchmark comparator for researchers studying newer metabolic peptides including GLP2 and GLP3.
Q: How does GLP1 differ from native GLP-1?
A: 94% homology to human GLP-1(7-37) but with a C-18 fatty di-acid side chain enabling albumin binding. This extends half-life from minutes to ~165 hours, allowing weekly administration in research.
Q: What is GLP1's research significance?
A: Extensive Phase 3 data makes it a benchmark GLP-1 agonist. Researchers use it as a comparator when studying newer compounds like GLP2 (dual agonist) and GLP3 (triple agonist).
Q: How does GLP1 work mechanically?
A: Activates GLP-1 receptors in the pancreas (glucose-dependent insulin secretion), hypothalamus (appetite regulation), and GI tract (delayed gastric emptying).
Related Research: GLP2 Research Peptide | GLP3 Research Peptide | Metabolic Research 2026 | Cagrilintide Research Peptide | AOD-9604 Research Peptide | Retatrutide Complete Research Guide | Are Research Peptides Legal? | What Is a COA?
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
| Lot # | Size | Test Date | COA |
|---|---|---|---|
| ARC-SEMAG10-004 | 10mg | Jun 24, 2026 | View PDF |
